Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K
Clinical cancer research : an official journal of the American Association for Cancer Research · 49 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
- Nonprofit
- Alliance for Clinical Trials in Oncology Foundation
- Government
- National Institutes of Health
- Government
- National Cancer Institute
- Government
- National Institute of General Medical Sciences
- Government
- NCI NIH HHS
- Government
- NIH
- Nonprofit
- Alliance for Clinical Trials in OncologyFoundation
- Government
- NIGMS NIH HHS
- Grants
- Alliance for Clinical Trials in Oncology Foundation (P50CA127003); National Cancer Institute (K07CA148894); National Cancer Institute (R01CA118553); National Institute of General Medical Sciences (U54-GM-104942); National Cancer Institute (U10 CA180821); National Cancer Institute (U10-CA180888); National Cancer Institute (UG1 CA233180); National Cancer Institute (U24 CA196171); National Cancer Institute (U10CA180830); National Cancer Institute (U10 CA180867); Alliance for Clinical Trials in Oncology Foundation (UG1CA189858); National Cancer Institute (U10CA180795); Alliance for Clinical Trials in Oncology Foundation (U10CA180826); Alliance for Clinical Trials in Oncology Foundation (U10CA180830); National Cancer Institute (U10CA180838); National Cancer Institute (R01 CA205406); National Cancer Institute (U10-CA180882); Alliance for Clinical Trials in Oncology Foundation (R01CA118553); Alliance for Clinical Trials in Oncology Foundation (U10CA180888); Alliance for Clinical Trials in Oncology Foundation (U24CA196171); National Cancer Institute (P50-CA127003); National Cancer Institute (UG1 CA189974); Alliance for Clinical Trials in Oncology Foundation (U10CA180795); National Cancer Institute (U10 CA180826); National Cancer Institute (UG1CA189858); Alliance for Clinical Trials in Oncology Foundation (K07CA148894); Alliance for Clinical Trials in Oncology Foundation (U10CA180838); Alliance for Clinical Trials in Oncology Foundation (R01CA205406); Alliance for Clinical Trials in Oncology Foundation (U10CA180867); National Institutes of Health (U10CA180 882); National Institutes of Health (U10-CA180821)
Based on 8 listed funder(s).
Publication
- Published
- 2019-09-23 · Clin Cancer Res · vol. 25 · issue 24 · pp. 7497–7505
- Publisher
- American Association for Cancer Research
- Cited
- 66 citations · more than 96% of similar papers · 4.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 47 works
- Access
- Open access (repository copy)
- Research areas
- Vitamin D Research Studies · Bone health and treatments · Estrogen and related hormone effects
- Keywords
- Medicine, Internal medicine, Colorectal cancer, Hazard ratio, Proportional hazards model, Oncology, Vitamin D and neurology, Cancer, Chemotherapy, Progression-free survival, Prospective cohort study, Confidence interval, Gastroenterology
- MeSH
- humans, colorectal neoplasms, neoplasm metastasis, vitamins, vitamin d, prognosis, survival rate, prospective studies, female, male
17 authors
From US
- Chen Yuan · correspondingDana-Farber Cancer Institute
- Kaori SatoDana-Farber Cancer Institute
- Bruce W. HollisMedical University of South Carolina
- Sui ZhangDana-Farber Cancer Institute
- Donna NiedzwieckiDuke University
- Fang‐Shu OuMayo Clinic; Mayo Clinic in Arizona; Mayo Clinic in Florida
Abstract
Purpose
Previous studies have suggested that higher circulating 25-hydroxyvitamin D [25(OH)D] levels are associated with decreased colorectal cancer risk and improved survival. However, the influence of vitamin D status on disease progression and patient survival remains largely unknown for patients with advanced or metastatic colorectal cancer.
Experimental design
We prospectively collected blood samples in 1,041 patients with previously untreated advanced or metastatic colorectal cancer participating in a randomized phase III clinical trial of first-line chemotherapy plus biologic therapy. We examined the association of baseline plasma 25(OH)D levels with overall survival (OS) and progression-free survival (PFS). Cox proportional hazards models were used to calculate hazard ratios (HRs) and confidence intervals (CIs), adjusted for prognostic factors and confounders.
Results
At study entry, 63% of patients were vitamin D deficient (P trend = 0.0009 and 0.03, respectively). Compared with patients in the bottom quintile of 25(OH)D (≤10.8 ng/mL), those in the top quintile (≥24.1 ng/mL) had a multivariable-adjusted HR of 0.66 (95% CI, 0.53-0.83) for OS and 0.81 (95% CI, 0.66-1.00) for PFS. The improved survival associated with higher 25(OH)D levels was consistent across patient subgroups of prognostic patient and tumor characteristics.
Conclusions
In this large cohort of patients with advanced or metastatic colorectal cancer, higher plasma 25(OH)D levels were associated with improved OS and PFS. Clinical trials assessing the benefit of vitamin D supplementation in patients with colorectal cancer are warranted.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.